




**ChemAxon**  
*discovery informatics*

# ChemAxon Science

Douglas Drake



# New Drug Approvals Hit 16-Year High In 2012\*

## *The good news for all you chemists*

In 2012: 26 of 39 new therapeutics approved by FDA were small molecule drugs

## *The ongoing challenge*

Regardless, drug discovery research is under extreme price pressure, resulting in:


- R & D organizations and companies becoming smaller, if not virtual
- Increasingly more R & D being done by academic labs or CROs
- Increased reliance on insilico techniques to direct wet lab work
- Strong interest and focus on data mining and text analytic tools to capture and highlight important data and relationships in public and internal sources

# ChemAxon has technologies to meet these challenges

- Open Innovation with Plexus
- InSilico Technologies with Reactor and Disco
- Predictive Informatics with Metabolizer
- Knowledge Management with D2S/  
D2DD, Naming



Let's be part of the solution, not part of the problem



**Somewhere, something went terribly wrong**

# Agenda

- 9 am
- **ChemAxon Science**  
*Doug Drake (ChemAxon)*
- 9:40 am
- **Metabolizer: Majors and Minors**  
*György Pirok (ChemAxon)*
- 11:55 am
- **ChemAxon's Compound Registration**  
*Ákos Papp (ChemAxon)*
- 11:55 am
- **Tool for the „Big Guys”: Towards Registration of Large Bio-Molecules**
- *Roland Knispel (ChemAxon)*
- 2:30 pm
- **Consultancy – Reaching the Parts other Products Can't Reach**
- *Tim Dudgeon & Erin Bolstad (ChemAxon)*
- 3:40 pm
- **Naming: Extracting Chemical Information within Documents - from Desktop to Enterprise**  
*Daniel Bonniot & David Deng (ChemAxon)*
- 12:50 pm